Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Central Nervous System Neoplasms
  • Cranial Irradiation
  • Immunotherapy
  • Lymphoma

abstract

  • The addition of rituximab to MPV increased the risk of significant neutropenia requiring routine growth factor support. Additional cycles of R-MPV nearly doubled the CR rate. Reduced-dose WBRT was not associated with neurocognitive decline, and disease control to date is excellent.

publication date

  • October 20, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.12.5062

PubMed ID

  • 17947720

Additional Document Info

start page

  • 4730

end page

  • 5

volume

  • 25

number

  • 30